Abstract

Bone marrow transplantation has been used for several years in the treatment of hematopoietic system malfunction. However, this particular therapy option has had minimal benefit when the hematopoietic system failure results from radiation exposure, such as that after the Chernobyl accident. In the last ten years, there has been considerable progress in the development of methods to encourage stem cell repopulation with the application of hematopoietic growth factors, and to reconstitute the hematopoietic system with stem cells extracted from the peripheral blood. Problems with allogeneic bone marrow or peripheral blood stem cell transplantation as a therapy option include graft-versus-host disease and a shortage of human leukocyte antigen (HLA)-matched donors. These problems can be overcome if an autologous bone marrow or peripheral blood transplant is performed, but this is not always practical. Another approach to combat these difficulties is the use of umbilical cord blood as a source of donor cells, since placental blood is rich in stem cells and less prone to lead to graft-versus-host disease than mature blood.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.